Shorter Radiation Schedule for the Treatment of Prostate Cancer
NCT ID: NCT00201916
Last Updated: 2010-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
936 participants
INTERVENTIONAL
1995-03-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
NCT01230866
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
NCT03570827
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
NCT04619069
Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer
NCT00116142
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
NCT00669162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
5250 cGy in 20 fractions over 28 days
5250 cGy/20 fractions over 28 days
see above
2
6600 cGy in 33 fractions over 45 days
6600 cGy/33 fractions over 45 days
see above
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
5250 cGy/20 fractions over 28 days
see above
6600 cGy/33 fractions over 45 days
see above
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stage T1a moderately or poorly differentiated, T1b, T1c or T2 by the current UICC-TNM classification
Exclusion Criteria
* previous therapy for carcinoma of the prostate other than biopsy or TURP, including patients previously on hormone therapy for treatment of their prostate cancer
* prior or active malignancy other than non-melanoma skin cancer; or colon or thyroid cancer treated a minimum of five years prior to study entry and presumed cured
* simulated volume exceeds 1000 cm3
* previous pelvic radiotherapy
* inflammatory bowel disease
* serious non-malignant disease which would preclude radiotherapy or surgical biopsy
* geographic inaccessibility for follow-up
* psychiatric or addictive disorder which would preclude obtaining informed consent or adherence to protocol
* unable to commence radiation therapy within 26 weeks of the date of last prostatic biopsy
* failure to give informed consent to participate in the study
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NCIC Clinical Trials Group
NETWORK
Ontario Clinical Oncology Group (OCOG)
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ontario Clinical Oncology Group
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Himu Lukka, MD
Role: STUDY_CHAIR
Juravinski Cancer Centre
Charles Hayter, MD
Role: STUDY_CHAIR
Toronto Sunnybrook Regional Cancer Centre
Mark Levine, MD
Role: PRINCIPAL_INVESTIGATOR
Ontario Clinical Oncology Group (OCOG)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
B.C. Cancer Agency - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
B. C. Cancer Agency - Vancouver Cancer Clinic
Vancouver, British Columbia, Canada
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Dr. Leon Richard Oncology Centre
Moncton, New Brunswick, Canada
Saint John Regional Hospital
Saint John, New Brunswick, Canada
Newfoundland Cancer Clinic
St. John's, Newfoundland and Labrador, Canada
Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada
Northeastern Ontario Regional Cancer Centre
Greater Sudbury, Ontario, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada
London Regional Cancer Centre
London, Ontario, Canada
Thunder Bay Regional Health Sciences Centre
Thunder Bay, Ontario, Canada
Toronto-Sunnybrook Regional Cancer Centre
Toronto, Ontario, Canada
University Health Network -Princess Margaret Hospital
Toronto, Ontario, Canada
Windsor Regional Cancer Centre
Windsor, Ontario, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005 Sep 1;23(25):6132-8. doi: 10.1200/JCO.2005.06.153.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAN-OCOG-V95-0687
Identifier Type: -
Identifier Source: secondary_id
OCOG-1995-PR.5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.